Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)

• Published in: BMJ open Vol. 12; no. 5; p. e062599
• Main Authors: Abhishek, Abhishek, Boyton, RJ, McKnight, Áine, Coates, Laura, Bluett, James, Barber, Vicki S, Cureton, Lucy, Francis, Anne, Appelbe, Duncan, Eldridge, Lucy, Julier, Patrick, Peckham, Nicholas, Valdes, Ana M, Rombach, Ines, Altmann, Daniel M, Nguyen-Van-Tam, Jonathan, Williams, Hywel C, Cook, Jonathan Alistair
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 03.05.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Antibodies; clinical trials; COVID-19; COVID-19 - prevention & control; COVID-19 Drug Treatment; COVID-19 Vaccines; Drug dosages; Humans; Immunocompetence; Immunosuppressive agents; Inflammatory diseases; Methotrexate - therapeutic use; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Rheumatology; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccines; COVID-19; rheumatologY; clinical trials
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-062599

IntroductionIt is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The objective of this study was to evaluate if a 2-week interruption in low-dose weekly methotrexate treatment after SARS-CoV-2 vaccine boosters enhances the immune response compared with continuing treatment in adults with autoimmune inflammatory conditions.Methods and analysisAn open-label, pragmatic, prospective, parallel group, randomised controlled superiority trial with internal feasibility assessment and nested mechanistic substudy will be conducted in rheumatology and dermatology clinics in approximately 25 UK hospitals. The sample size is 560, randomised 1:1 to intervention and usual care arms. The main outcome measure is anti-spike receptor-binding domain (RBD) antibody level, collected at prebooster (baseline), 4 weeks (primary outcome) and 12 weeks (secondary outcome) post booster vaccination. Other secondary outcome measures are patient global assessments of disease activity, disease flares and their treatment, EuroQol 5- dimention 5-level (EQ-5D-5L), self-reported adherence with advice to interrupt or continue methotrexate, neutralising antibody titre against SARS-CoV-2 (mechanistic substudy) and oral methotrexate biochemical adherence (mechanistic substudy). Analysis of B-cell memory and T-cell responses at baseline and weeks 4 and 12 will be investigated subject to obtaining additional funding. The principal analysis will be performed on the groups as randomised (ie, intention to treat). The difference between the study arms in anti-spike RBD antibody level will be estimated using mixed effects model, allowing for repeated measures clustered within participants. The models will be adjusted for randomisation factors and prior SARS-CoV-2 infection status.Ethics and disseminationThis study was approved by the Leeds West Research Ethics Committee and Health Research Authority (REC reference: 21/HRA/3483, IRAS 303827). Participants will be required to give written informed consent before taking part in the trial. Dissemination will be via peer review publications, newsletters and conferences. Results will be communicated to policymakers.Trial registration number ISRCTN11442263.